Therapeutic cannabis
Understanding the stakes of medical cannabis
Therapeutic cannabis
Understanding the stakes of medical cannabis
Therapeutic cannabis
Understanding the stakes of medical cannabis
The resurgence of an ancestral plant
The resurgence of an ancestral plant
Therapeutic use, a universal plant
Cannabis has been used in medicine for several hundred years. First of all, different ethnic groups and societies have made use of it. It was in the seventeenth century that cannabis entered western medicine for the treatment of epilepsy, migraines, neuralgia, convulsions, spasms and other ailments.
For various reasons (inconstancy of the therapeutic activity of cannabis, difficulty in fixing the dosage, etc.), treatments disappeared in the first half of the 20th century. It is around 1970, following various works, that the interest for this plant reappeared. A high number of claims about therapeutic benefits have led to an increasing number of therapists supporting the use of cannabis to treat certain physical and mental illnesses.
Cannabis today
At the international level, in reviewing a series of World Health Organization (OMS) recommendations on cannabis and its derivatives, the United Nations Commission on Narcotic Drugs (CND) decided to remove it from Schedule IV of the Single Convention on Narcotic Drugs of 1961.
On the national territory, the health authorities have set up a therapeutic cannabis program. The work of successive committees of the French National Agency for the Safety of Medicines (ANSM) has paved the way for an experiment that will soon allow 3,000 patients to benefit from a therapeutic cannabis prescription.
Cannabis today
Cannabis today
At the international level, in reviewing a series of World Health Organization (OMS) recommendations on cannabis and its derivatives, the United Nations Commission on Narcotic Drugs (CND) decided to remove it from Schedule IV of the Single Convention on Narcotic Drugs of 1961.
On the national territory, the health authorities have set up a therapeutic cannabis program. The work of successive committees of the French National Agency for the Safety of Medicines (ANSM) has paved the way for an experiment that will soon allow 3,000 patients to benefit from a therapeutic cannabis prescription.
Innovations to come
The level of knowledge in the different areas of medical use of cannabis and cannabinoids is very heterogeneous.
Pre-clinical and clinical trials on certain cannabinoids should be conducted to support the use of cannabis products.
Innovations to come
Innovations to come
The level of knowledge in the different areas of medical use of cannabis and cannabinoids is very heterogeneous.
Pre-clinical and clinical trials on certain cannabinoids should be conducted to support the use of cannabis products.